Trial Profile
A Randomised Controlled Clinical Trial of the Efficacy of HAART Intensification With Raltegravir in HIV Virally Suppressed Patients With Cognitive Impairment
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 30 Sep 2022
Price :
$35
*
At a glance
- Drugs Raltegravir (Primary) ; Antiretrovirals
- Indications HIV infections
- Focus Therapeutic Use
- Acronyms HANDral
- 15 Jan 2014 Planned End Date changed to 1 Oct 2013 as reported in ClinicalTrials.gov record.
- 15 Jan 2014 Status changed from not yet recruiting to discontinued as reported in ClinicalTrials.gov record.
- 10 Oct 2011 New trial record